Skip to main content

Science
Products
Stories
Newsroom
About

Investors Media Careers Partners

Careers
Investors

Changed

Changed

How can we help you?

0 search results for

Suggestions within Pfizer.com

Home
News
Press Releases

Press Release Archive

Press Releases

Year

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

2014

2013

2012

2011

2010

2009

2008

2007

Month

January

February

March

April

May

June

July

August

September

October

November

December

View 12

View 24

View 48

Categories

Corporate
Financial
Prescription Medicines
Research and Pipeline
Social Responsibility
Vaccines

Keywords

All Keywords

Covid-19
Finance
Investments
Leadership
Medicines
Partnerships
Research
Responsibility
Vaccines

May 2024

05.06.2024
Pfizer Announces New Chief Strategy and Innovation Officer
- Leadership
05.01.2024
Pfizer Reports First-Quarter 2024 Results

April 2024

04.29.2024
FDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical Cancer
- Prescription Medicines
- Medicines
04.29.2024
Pfizer Highlights Progress in Accelerating Breakthrough Cancer Medicines at ASCO 2024 Annual Meeting
- Research and Pipeline
04.26.2024
U.S. FDA Approves Pfizer’s BEQVEZ™ (fidanacogene elaparvovec-dzkt), a One-Time Gene Therapy for Adults with Hemophilia B
- Prescription Medicines
- Medicines
04.25.2024
Pfizer Announces 2024 Shareholder Meeting Preliminary Results
- Corporate
- Finance
04.24.2024
Pfizer Declares Second-Quarter 2024 Dividend
- Corporate
- Finance
04.22.2024
European Commission Approves Pfizer’s EMBLAVEO® for Patients with Multidrug-Resistant Infections and Limited Treatment Options
- Prescription Medicines
- Medicines
04.11.2024
Pfizer Invites Shareholders to Attend Virtual-Only 2024 Annual Meeting of Shareholders on April 25
- Corporate
- Finance
04.09.2024
Pfizer Announces Positive Top-Line Results from Phase 3 Study of ABRYSVO® in Adults Aged 18 to 59 at Increased Risk for RSV Disease
- Vaccines
- Vaccines

March 2024

03.20.2024
Pfizer Invites Public to View and Listen to Webcast of May 1 Conference Call with Analysts
- Financial
- Finance
03.13.2024
European Commission Approves Pfizer’s PREVENAR 20® to Help Protect Infants and Children Against Pneumococcal Disease
- Vaccines
- Vaccines

Page 8
Page 9
Current page 10
Page 11
Page 12

Media Resources & Contact Information

Media Contacts
Press Kits

Anyone may view our press releases, press statements, and press kits.

However, to ensure that customers, investors, and others receive the appropriate attention, Pfizer media contacts may only respond to calls and emails from professional journalists.

Investors
Media
Careers
Partners

PfizerForAll
Healthcare Professionals
Grant Seekers
Business to Business

Privacy Statement
Accessibility Statement
Terms of Use
Contact Us

Glossary

© 2025 Pfizer Inc. All rights reserved

This information—including product information—is intended only for residents of the United States.

The products discussed herein may have different labeling in different countries.

Twitter
Facebook
Linked In
Instagram
Youtube